ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)
Aug 13, 2013 ·
8m 39s
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Information
| Author | cancerGRACE |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
